Home Cardiovascular PharmaWatch: Novartis Pays $150 Million to Pursue Transformational Cardiovascular Disease Therapy

PharmaWatch: Novartis Pays $150 Million to Pursue Transformational Cardiovascular Disease Therapy

139
0
cardiovascular

As reported in West Globe Newswire, Novartis has announced its’ move into developing a targeted cardiovascular therapy by exercising an option to license the rights to develop and commercialize TQJ230, an investigational agent preciously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals. Novartis paid $150 million to Akcea Therapeutics. Moving forward the Swiss giant is responsible for worldwide development and commercialization of TQJ230.  Presently, millions of people struggle with elevated lipoprotein(a) (Lp(a)), an independent cardiovascular disease (CVD) risk factor that cannot be effectively addressed by diet and other lifestyle changes.  If approved by regulatory agencies, TQJ230 could be first-in-class treatment specifically targeting elevated Lp(a).

Millions of people have elevated Lp(a), an independent inherited cardiovascular disease (CVD) risk factor. It is estimated that 20-30% of people who suffer from CVD have elevated Lp(a).[1],[2] Currently no treatment exists that specifically targets elevated Lp(a), and diet and other lifestyle changes are also not effective at reducing elevated levels.[3] Results of a Phase 2 study presented at AHA in November 2018 showed that TQJ230 significantly reduced Lp(a) in patients with high Lp(a) and pre-existing CVD.[4] Novartis plans to conduct a Phase 3 cardiovascular outcomes trial with the potential of addressing the Lp(a) patient community’s unmet need for effective treatment.

“No treatments are currently available to substantially lower Lp(a). People with this inherited risk factor are facing cardiovascular risks that cannot be addressed effectively with lifestyle changes,” said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “We’re excited about the novel, RNA-targeting approach that could be a game-changer for people with elevated Lp(a). If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option and another pillar of our longstanding commitment to re-imagining cardiovascular medicine.”

What is Lipoprotein(a) (Lp(a))
Lp(a) is a lipoprotein that travels through the blood. Elevated levels of Lp(a) collect in the arteries, gradually narrowing the arteries and limiting blood supply to the heart, brain, kidneys and legs. This can lead to increased risk of coronary heart disease, atherosclerosis, thrombosis and stroke.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.